30
Participants
Start Date
December 11, 2022
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
Allogenic CD19 CAR-γδT cell
Phase 1 dose escalation (3+3) : dose 1 (6 × 10\^6 cells/kg) , dose 2 (1.2 × 10\^7 cells/kg), dose 3 (1.8 × 10\^7 cells/kg); Phase 2 : dose of RP2D.
Fludarabine
Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
Cyclophosphamide
Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
RECRUITING
School of phamaceutical, Tsinghua University, Beijing
RECRUITING
Biotherapeutic Department, Chinese PLA General Hospital, Beijing
Chinese PLA General Hospital
OTHER